Saturday 17 October 2026
Export BEAM’s income statement to Excel — free account
Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024. In the quarter to June 2026, revenue fell 94.2%, EPS fell 18.0% and free cash flow grew 13.9%, each against the same quarter a year earlier.
23.47
1.26
−5.10%
Follow BEAM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
22.95 | 15.00 | 19.62 | 44.69 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(54.17) | (19.15) | (32.92) | (30.55) | |
P/B ratio |
3.35 | 2.11 | 2.21 | 2.58 | |
Price to Tangible BV |
3.35 | 2.11 | 2.21 | 2.58 | |
EV/Sales |
16.20 | 8.23 | 11.86 | 28.28 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.03) | (3.65) | (4.80) | (4.66) | |
EV/FCF |
(6.78) | (3.52) | (4.60) | (4.47) | |
Quick Ratio |
14.25 | 16.25 | 12.85 | 5.89 | |
Current Ratio |
14.57 | 16.99 | 13.09 | 6.02 | |
Net Debt/EBITDA |
8.51 | 10.65 | 82.82 | 8.57 | |
Debt/Assets |
7.23% | 6.77% | 0.00% | 0.00% | |
Debt/Equity |
0.09 | 0.09 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.11 | 0.11 | 0.04 | |
Operating CF/Net income |
0.54 | 1.36 | (0.34) | 0.72 | |
Capex/Depreciation |
(0.84) | (0.78) | (1.55) | (3.78) | |
Research and Development Expense of Revenue |
19,407.35% | 329.33% | 87.00% | 1,131.87% | |
Selling, General and Administrative Expense of Revenue |
6,519.80% | 108.48% | 28.29% | 275.73% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3,934.29% | 60.00% | 17.92% | 234.55% | |
Graham Net Nets |
0.24 | 0.39 | 0.37 | 0.30 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.39%) | (2.69%) | (3.50%) | (18.25%) | |
Free Cash Flow Yield |
(10.41%) | (15.60%) | (13.13%) | (14.15%) | |
Revenue per Share |
0.00 | 0.31 | 1.15 | 0.09 | |
Operating CF per Share |
(0.63) | (1.24) | (0.84) | (0.79) | |
Capex per Share |
(0.02) | (0.02) | (0.04) | (0.05) | |
Free Cash Flow per Share |
(0.66) | (1.27) | (0.88) | (0.84) | |
Cash per Share |
11.05 | 11.73 | 12.59 | 10.48 | |
Shareholders Equity per Share |
10.23 | 11.28 | 12.52 | 9.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.23 | 11.28 | 12.52 | 9.42 | |
Free Cash Flow |
(68.51) | (130.74) | (87.02) | (86.49) | |
Working Capital |
1,097.71 | 1,192.39 | 1,171.75 | 915.99 | |
Capital Expenditures |
(2.41) | (2.23) | (3.73) | (5.01) | |
Net Current Asset Value |
859.68 | 950.59 | 1,025.87 | 753.47 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
4.93 | 0.07 | 0.03 | 0.52 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
11.83 | 9.99 | 7.05 | 6.68 | |
Average Assets |
1,388.76 | 1,473.86 | 1,292.50 | 1,241.22 | |
Average Common Equity |
1,057.13 | 1,143.79 | 985.95 | 878.66 |
Columns are period end dates